[Featured Stock] SK Bioscience Rises Ahead of First Domestic COVID-19 Vaccine Approval

SK Bioscience's recombinant protein COVID-19 vaccine 'Skycovione Multi (GBP510)'. / Photo by SK Bioscience

[Asia Economy Reporter Myunghwan Lee] SK Bioscience is on the rise from the early trading session on the 28th. This is interpreted as investors' expectations gathering as the approval for the country's first domestically developed COVID-19 vaccine, 'Skycovione (GBP510)', is imminent.

As of 9:25 AM today, SK Bioscience is trading at 111,500 KRW, up 2.29% (2,500 KRW) compared to the previous trading day. On the 27th, the day before, SK Bioscience also closed at a price 6.34% higher.

According to the Ministry of Food and Drug Safety, on the afternoon of the 26th, the Central Pharmaceutical Affairs Deliberation Committee concluded that SK Bioscience's Skycovione Multi-dose Injection "can be approved." Although the final advisory from the final inspection committee for COVID-19 vaccines and treatments remains, it appears that the overall review regarding the vaccine's efficacy, safety verification, and post-approval safety assurance measures has been practically completed.

This content was produced with the assistance of AI translation services.